Kantar's research shows 31 per cent of Canadians surveyed said their taste in food had changed since being on the drug. In ...

This article highlights the impact of diabetes on the community, with 13% of adults in Florence County living with the ...

Medicare will pay an average of 36 percent less for 15 of its most expensive prescription drugs starting in 2027, the U.S. health plan said ...

The Trump administration negotiated lower prices on 15 costly drugs under Medicare, including Ozempic and Wegovy.

For a limited time, patients can get a steep discount on the popular medications, as long as they’re paying out of pocket Steve Christo/Corbis/Corbis/Getty Ozempic ...

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without insurance. The drugmaker said Monday that it has started selling higher doses ...

The previous price for Wegovy without insurance was $499. The cash price for popular weight-loss medications Wegovy and Ozempic is dropping by 30% in the U.S. on Monday, according to Novo Nordisk, the ...

Novo Nordisk (NVO) has cut the price of its weight-loss injection Wegovy by as much as 37% from its launch price in India, as the Danish drugmaker plays catch-up with rival Eli Lilly (LLY), whose ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

The long-term side effects of Wegovy® may include problems with your pancreas, kidneys, or gallbladder. These side effects are rare. For many, Wegovy® is safe to use long-term, and the benefits ...

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took Wegovy. By Dani Blum A new analysis of a major clinical trial ...